MedTrace Logo

An Open Label Study for Palmar Hyperhydrosis

NCT04906655 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2021-05-28

No results posted yet for this study

Summary

The purpose of this open-label study is to evaluate the efficacy and safety of different methods of application of glycopyrronium cloth, 2.4% in patients with palmar hyperhidrosis

Conditions

  • Palmar Hyperhidrosis
  • Hyperhidrosis
  • Sweat Gland Diseases
  • Skin Diseases

Interventions

DRUG

Glycopyrronium 2.4 % Medicated Cloth

The investigational product (glycopyrronium cloth, 2.4%) is a pre-moistened, medicated cloth towelette that comes in individually wrapped packets. Subjects will receive marketed Qbrexza, one box, containing 30 pouches.

Sponsors & Collaborators

  • Virginia Clinical Research, Inc.

    collaborator OTHER

  • Pariser, Robert J., M.D.

    lead OTHER

Principal Investigators

  • David M Pariser, MD · Virginia Clinical Research, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
9 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-01
Primary Completion
2021-05-20
Completion
2021-05-20
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04906655 on ClinicalTrials.gov